IMPORTANCE Diabetes in pregnancy is associated with a 2-times to 3-times higher rate of very preterm birth than in women without diabetes. Very preterm infants are at high risk of death and severe morbidity. The association of maternal diabetes with these risks is unclear.
D iabetes affects hundreds of millions of people. The incidence is compounded by obesity and is increasing in many parts of the world, including in women of reproductive age. 1, 2 Diabetes and obesity are significant risk factors for spontaneous and indicated preterm delivery (<37 weeks' gestation). [2] [3] [4] Despite advances in the care of women with pregestational diabetes (types 1 and 2), rates of preterm delivery remain 3-to 5-fold higher in women with diabetes than in the general obstetric population without diabetes. [5] [6] [7] Furthermore, the risk of preterm delivery is significantly increased in pregnancies with gestational diabetes. 8 Worldwide, approximately 11% of births are preterm and the incidence is rising. 9 Preterm birth is a major contributor to the global burden of disease. 10, 11 Infants born with very low birth weights (<1500 g) or who are very preterm (<32 weeks' gestation) constitute 1% to 2% of all births but account for up to half of all neonatal and infant deaths, 12 a significant proportion of childhood disability 13 and high health care costs. 12 In offspring of women with diabetes, preterm birth is the most important contributor to neonatal morbidity. 14 While the obstetric risks that are associated with diabetes in pregnancy are fairly well established, as is knowledge of the increased risks of malformations, fetal death, fetal macrosomia, and neonatal hypoglycemia, less is known about other neonatal outcomes. [5] [6] [7] 15 In particular, it is unclear how maternal diabetes affects infants who are born very preterm. The few studies that address this question describe conflicting results. One article indicated a higher risk of respiratory distress syndrome (RDS) in preterm infants born to mothers with diabetes vs infants born to mothers without diabetes, 16 while other studies did not detect a difference in the risk of RDS. 17 Preterm infants born to mothers with diabetes have even been reported to have a lower risk of bronchopulmonary dysplasia than infants born to mothers without diabets. 18 However, an increased risk of necrotizing enterocolitis (NEC), neonatal sepsis, and small head circumference at follow-up were recently reported for extremely preterm infants born to mothers with type 1 diabetes. 19, 20 The overall research question was to fill the previously mentioned gap in knowledge and to provide solid estimates for neonatal outcomes in very preterm infants born to mothers with diabetes. Given the comparatively low prevalence of maternal diabetes and the low incidence of very preterm birth, large sample sizes are required to accurately estimate neonatal risks that are associated with maternal diabetes. The International Network for Evaluating Outcomes in Neonates (iNeo) is a collaboration between neonatal networks from high-income countries with the goal of improving outcomes for children born very preterm and with a very low birth weight. 21 With detailed information on more than 100 000 infants, the iNeo database offers an opportunity to assess the associations of maternal diabetes with neonatal outcomes. We hypothesized that any maternal diabetes would increase the risk of in-hospital mortality and morbidity in very preterm infants with birth weights of fewer than 1500 g.
Methods

Setting
The study used data from national neonatal networks in 7 highresource countries in 3 continents: Canada, Finland, Israel, Italy, Japan, Sweden, and the United Kingdom. The participating networks and the iNeo Coordinating Centre at the Maternal-Infant Research Centre, Mount Sinai Hospital in Toronto, Ontario, Canada, obtained data sharing agreements and research ethics approval for data collection and transfer. The rules and regulations of each country were followed and ethics approval was obtained by each individual country. All participants were informed about the collection of the data in the register with the purpose of quality assessment of care and research.
Data Sources
Prospectively collected individual-level data from the following neonatal networks were included: Canadian Neonatal 
Study Population
The study population included all singleton infants born alive in high-income countries who were very preterm (24-31 weeks' gestation) and with a birth weight of less than 1500 g. The database did not hold information on stillbirths. Multiple pregnancies and major congenital malformations were excluded. The study period covered 9 years from January 1, 2007 , to December 31, 2015 .
Main Exposure
A diagnosis of any type of pregestational diabetes or gestational diabetes, recorded in tick boxes (pregestational or gestational diabetes were ticked if "yes") or defined according to ICD 10 codes, was recorded as a dichotomous variable in the iNeo database. Differentiating between pregestational and gestational diabetes was not possible, and information on the duration of diabetes or the type of treatment (insulin or oral antidiabetic agents) was not available. The definitions and screening protocols for diabetes in pregnancy used in the participating countries are provided in eTable 1 in the Supplement.
Outcomes
The main outcome was in-hospital infant mortality. Secondary outcomes included a composite of mortality and severe neonatal morbidity. In addition, severe and major morbidities were analyzed as separate outcomes. 
Covariates
Covariates and potential confounders included advanced (≥35 years) maternal age at delivery, hypertensive disorder of pregnancy (chronic hypertension, gestational hypertension, preeclampsia, eclampsia, or HELLP syndrome), any treatment with antenatal corticosteroids, mode of delivery, delivery outside of a tertiary center (outborn; for all networks but UKNC), gestational age (GA) at delivery, sex, birth weight z score, and neonatal network.
Statistical Analysis
Maternal and infant characteristics and outcomes were compared between neonates born to mothers with and without diabetes. Frequency (percentage) or means with standard deviations were reported. Differences were assessed with Pearson χ 2 and the t test for categorical variables and continuous variables, respectively. Univariate and multivariable logistic analyses were applied for primary and secondary outcomes. Odds ratios (ORs) with 95% confidence intervals were estimated. In the adjusted analyses, covariates were included as confounders based on the literature or statistical significance. Maternal age was introduced as a dichotomous variable (ie, age ≥35 years, yes or no) and GA was analyzed by week and birth weight as z scores. Two regression models were used: model 1 included the following possible confounders: a maternal age of 35 years or older, maternal hypertensive disorder in pregnancy, GA, sex, birth weight z score, and network. Model 2 included the variables in model 1 as well as antenatal treatment with corticosteroids, mode of delivery, and outborn status. Stratified analyses by GA, sex, and network were also performed.
Finally, propensity score (PS) matching was used, stratified by networks. The PS represented a single-index variable summarizing the maternal and perinatal covariates known or hypothesized to be either related to the exposure (maternal diabetes) or the neonatal outcomes. Matching the PS among infants born to mothers with diabetes to that of infants born to mothers without diabetes was performed using the SAS macro "match.sas" (SAS Institute) and was based on a caliper width of 0.2 times the standard deviation of the logit-transformed PS. Within each matched sample (n = 2914 pairs), covariates were tested for balance using paired t tests for continuous variables, and the McNemar tests for categorical covariates. The association between maternal diabetes and neonatal outcomes in each matched sample was examined using logistic regression analyses as described previously, using generalized estimating equations with an unstructured correlation. All analyses were conducted using SAS, version 9.4 (SAS Institute) with a 2-sided significance level of P = .05. The statistic package R (R Foundation) was applied to generate the plot.
Results
Between January 1, 2007, and December 31, 2015 , there were 78 126 singleton eligible infants, 76 360 (95.7%) of whom had information on maternal diabetes; 3280 (4.3%) infants were born to mothers with diabetes. Compared with mothers without diabetes, women with diabetes were older, had more hypertensive complications, were administered antenatal corticosteroids more often, and had cesarean deliveries more frequently ( Table 1) . Infants of mothers with diabetes had a higher GA and higher birth weight but lower mean birth weight z score than infants of mothers without diabetes. The rate of small for GA was similar between infants with mothers with and without diabetes; infants born to mothers without diabetes were born outside a tertiary unit more often than infants of mothers with diabetes ( Table 1) . Infants of mothers with diabetes had lower crude risks of in-hospital mortality and the composite of in-hospital mortality or severe neonatal morbidity (IVH grade 3-4, cPVL, treated ROP, or BPD) than infants of mothers without diabetes ( Table 2) . Similarly, infants of mothers with diabetes had lower rates of IVH grade of 3 to 4, treated ROP, treated patent ductus arteriosus, and BPD than infants of mothers without diabetes. In contrast, the crude risks of RDS and NEC were higher in infants of mothers with diabetes than in infants of mothers without diabetes. After adjusting for confounders (model 1), infants of mothers with diabetes had a lower risk of IVH. This difference disappeared after further adjustment for antenatal steroid treatment, mode of delivery, and outborn status (eTable 2 in the Supplement). In the final step using PS matched analyses, the risk estimates for adverse neonatal outcomes remained similar between the 2 groups (Table 2, Figure) .
A stratified analysis by GA week was conducted to identify GA-related risks of maternal diabetes. Infants of mothers with diabetes had a significantly higher risk of mortality at 26 weeks' gestation and mortality or severe morbidity at 31 weeks' gestation than infants of mothers without diabetes, while no difference in risk was found in other GA strata (test for an interaction between maternal diabetes and GA on in-hospital mortality: GA [SE], −0.02 [0.03]; P =.58)( Table 3 ). The rate of in-hospital mortality or severe neonatal morbidity in very preterm infants of mothers with diabetes varied from 23% to 39% across the 7 networks, but the adjusted odds of adverse outcomes in infants of mothers with diabetes did not differ significantly from that in infants of mothers without diabetes (test for interaction between maternal diabetes and network on in-hospital mortality: Canadian Neonatal Network [SE] Severe neonatal morbidity was indicated by an intraventricular hemorrhage (IVH) grade of 3 to 4, cystic periventricular leukomalacia (cPVL), and severe retinopathy of prematurity (ROP) that needed treatment or bronchopulmonary dysplasia (BPD). Propensity score-matched odds ratios were stratified by network. The infants were very preterm infants (<32 weeks of gestation) and were considered very low birth weight (<1500 g). NEC indicates necrotizing enterocolitis; PDA, patent ductus arteriosus; RDS, respiratory distress syndrome.
Figure. Association of Maternal Diabetes and Adverse Neonatal Outcomes After Very Preterm Birth
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Association of Maternal Diabetes with Neonatal Outcomes of Very Preterm and Very Low-Birth-Weight Infants P = .10) (eTable 2 in the Supplement). Girls of mothers with diabetes had a significantly higher risk of in-hospital mortality (adjusted OR, 1.37; 95% CI, 1.06, 1.77) than girls of mothers without diabetes (eTable 3 in the Supplement).
Discussion
This study has 3 clinically important findings: (1) very preterm infants born to mothers with diabetes are not at a higher risk of in-hospital mortality or morbidity than the population without diabetes, (2) the odds for adverse neonatal outcomes in very preterm infants born to mothers with diabetes did not vary between countries despite different screening and diagnostic protocols for gestational diabetes, and (3) the results are consistent for most GAs, both sexes, and all national populations assessed.
Strength and Limitations
To our knowledge, this study is the largest with adequate power to detect clinically important associations of maternal diabetes with neonatal outcomes of very preterm infants. The number of infants was sufficient to assess outcomes by week of GA and for boys and girls independently. Data on diabetes exposure and outcomes were collected according a standardized protocol, limiting information bias. With data on very preterm births from 7 countries on 4 different continents, we believe that our results have high external validity because of the various diabetes protocols used and populations. Our study also has limitations. The most important is that although individual databases, such as that from the UKNC and the Swedish Neonatal Quality Register, contain details on all admissions to neonatal care, the iNeo database, like some international databases, such as the Vermont Oxford Network, only includes information on infants with birth weights of 1500 g or less. Maternal diabetes may lead to either restricted or enhanced fetal growth. By including only infants with a birth weight of less than 1500 g we have excluded a significant portion of very preterm infants with birth weights above the mean, particularly those born at 29 to 31 weeks' gestation. However, the risk of neonatal mortality and morbidity in infants of mothers with diabetes born at 28 to 31 weeks' gestation was not significantly different than that of infants born before 28 weeks (including large-for-GA infants), suggesting that this limitation may not have introduced a significant selection bias.
Our study was restricted to live births and we did not have information on abortions or fetal deaths before 24 weeks of gestation. The risks of fetal death due to factors like major malformations and placental insufficiency are higher in pregnancies with maternal diabetes. Thus, it is possible that the offspring included in the study reflect a selection of healthier pregnancies, which may have led to an underestimation of the risks associated with maternal diabetes and preterm birth.
Moreover, the data did not enable us to differentiate the type of maternal diabetes (ie, type 1, type 2, or gestational diabetes), and we had no information on the level of glycemic control before or during pregnancy or on diabetes-related complications (except for hypertensive disorders in pregnancy). Despite accounting for many important confounders, we cannot exclude residual confounding by unmeasured or unknown confounders. Neonatal outcomes differed slightly between networks, which may reflect differences in definitions, screening programs, and obstetric interventions. However, the lack of difference in the risk of infants of mothers with or without diabetes was consistent through all networks.
Comparison With Other Studies
Overall, we did not identify increased odds of mortality or severe morbidity in infants born very preterm to mothers with diabetes when compared with infants of mothers without diabetes. This is largely in keeping with data from previous studies, 17, 19, 20, 31 even though some studies report an increased adjusted risk of NEC in infants of mothers with diabetes. 19, 20 We also identified higher crude risks of NEC and RDS in infants of mothers with diabetes than infants of mothers without diabetes, but after adjusting for potential confounders there were no significant differences. Notably, women with diabetes had significantly more risk factors than women without diabetes. On the other hand, antenatal treatment with corticosteroids, cesarean delivery, and delivery at a tertiary unit were more common in pregnancies with diabetes. This is likely a reflection of a more intense monitoring of these high-risk pregnancies. Similar to our study, Grandi et al 20 reported that women with diabetes delivering very preterm were more likely to have received antenatal care compared with controls without diabetes, and a study from Israel reported a higher proportion of antenatal corticosteroid treatment in pregnancies with maternal diabetes than nondiabetic pregnancies.
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Importantly, in our study infants of mothers with diabetes were born at a later GA than infants of mothers without diabetes. Our results align with several other studies, 17,20 while others found opposite results 19 or no significant difference in GA (or birth weight) between infants of mothers with or without diabetes. 31 In our study, the higher mean GA at delivery of infants of mothers with diabetes is likely to have attenuated the crude neonatal risks associated with diabetes.
Indeed, GA has been demonstrated to be the most important predictor of morbidity in infants of mothers with diabetes 14 as well as mothers without diabetes. The outlook for women with diabetes and their infants has improved significantly over the last decade following the use of a more active diabetes management strategy before and during pregnancy. 5, 8, 32, 33 However, the rates of both spontaneous and indicated preterm birth increased several-fold over the same period. 3 Risk factors for preterm birth in pregnancies with diabetes include a history of preterm birth, unsatisfactory metabolic control, a premature rupture of membranes that is associated with urogenital infections, diabetes-related complications (such as chronic hypertension), preeclampsia, and, in particular, overt nephropathy. 3, [34] [35] [36] [37] Even incipient nephropathy (ie, microalbuminuria) was demonstrated to increase the risk of preterm birth in pregnancies with maternal diabetes. 38 However, maternal hyperglycemia in diabetes, assessed as elevated hemoglobin A 1c levels throughout pregnancy, is an independent risk factor for adverse pregnancy outcomes also in women without signs of microvascular or macrovascular diabetes-related complications. 34 We could not address this concern in this study as we did not have information on either the level of glycemic control or on the type of diabetes. The 2-hour glucose cutoff for diagnosis of gestational diabetes after oral glucose tolerance test varied between countries, spanning from 140 mg/dL (to convert to micromoles per liter, multiply by 0.0555) (United Kingdom) to 180 mg/dL (Sweden). These differences most likely contributed to some of the network variation in prevalence of maternal diabetes among very preterm births, spanning from 1.8% in Sweden to 12% in Finland. Sweden has, next to Finland, the highest incidence of type 1 diabetes in the world. 39 Even so, only about 0.4% of pregnancies in Sweden are complicated by type 1 diabetes 5 and gestational diabetes is much more common than pregestational diabetes. Therefore, in this study, the higher prevalence of diabetes in pregnant Finnish women than pregnant Swedish women is likely a reflection of different screening protocols and diagnostic criteria for gestational diabetes in the 2 countries (eTable 1 in the Supplement). However, despite the varying prevalence of the different types of diabetes, all networks reported similar odds for adverse neonatal outcomes for very preterm infants of mothers with diabetes compared with mothers without diabetes. Thus, very preterm birth is a strong risk factor for neonatal mortality and morbidity, irrespective of maternal diabetes. Our study found similar risks of mortality and morbidity in boys and girls born to mothers with diabetes. This is in accordance with previous findings in pregnancies with diabetes, 40 but in contrast to reports from the general obstetric population, in which boys face an excess risk of mortality and morbidity.
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Conclusions
Diabetes in pregnancy is a significant risk factor for very preterm birth. However, in high-resource settings, diabetes in pregnancy is not associated with an increased risk of inhospital neonatal mortality or severe morbidity in infants born before 32 weeks and with a birth weight of less than 1500 g. Role of the Funder/Sponsor: The funding organizations played no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
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